StockData
Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc. (CAPR) stock

CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$8.41+0.11 (+1.33%)

Close on Nov 17, 2026Market cap $488.95MP/E –Yield –

Capricor Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Capricor Therapeutics's pe ratio was 41.9× on Jan 31, 2019, against 160.0× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2019Jan 31, 201941.9×+8.2
2018Dec 31, 201833.7×−126.3
2013Jan 31, 2013160.0×+93.3
2012Dec 31, 201266.7×−201.1
2011Dec 30, 2011267.7×–

More Capricor Therapeutics figures

See a number that looks wrong?